Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 3Brain Neoplasms 2Pituitary Neoplasms 1Non-Melanoma Skin Cancer (NMSC) 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Neoplasms 1Neoplasm, Residual 1Keratosis, Actinic 1Central Nervous System Neoplasms 1

Interventions

Blood Specimen Collection 6Liquid Biopsy 3Chemotherapy, Adjuvant 2trastuzumab deruxtecan 1pegaspargase 1Vincristine 1Trastuzumab 1Transplantation, Autologous 1Prednisone 1Neoadjuvant Therapy 1Methotrexate 1Mercaptopurine 1Hematologic Tests 1Drug Therapy 1Doxorubicin 1Daunorubicin 1Cytoreduction Surgical Procedures 1Cytarabine 1Cyclophosphamide 1Clonal Evolution 1Anti-Inflammatory Agents, Non-Steroidal 1Aminolevulinic Acid 1Ado-Trastuzumab Emtansine 1Adjuvants, Pharmaceutic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Neoplasm, Residual × Aminolevulinic Acid × Clear all
NCT05850377 2023-05-09

5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas

Sociedad de Lucha Contra el Cáncer del Ecuador

Not yet recruiting
90 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Central Nervous System Neoplasms, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡